Abstract 1549: Preclinical characterization of GQ1010, a next generation Trop2 ADC with the best-in-class potential against diverse Trop2+ solid tumors

体内 医学 癌症研究 抗体-药物偶联物 喜树碱 治疗指标 离体 细胞毒性 胰腺癌 癌症 体外 药理学 药品 抗体 单克隆抗体 化学 内科学 免疫学 生物 生物化学 生物技术 有机化学
作者
Yajun Sun,Mingyu Hu,Cao Lv,Yu Si,Xiao Liu,Xinju Gao,Dong Yang,Guangming Chen,Boyu Zhong,Tony Zhang,Lili Shi,Gang Qin,Paul H. Song
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:83 (7_Supplement): 1549-1549 被引量:1
标识
DOI:10.1158/1538-7445.am2023-1549
摘要

Abstract Background: While Trop2-targeting antibody-drug conjugates (ADC) have demonstrated meaningful clinical response for the treatment of solid tumors, these ADCs still exhibit significant safety issues that limit the full potential of Trop2 ADCs. GQ1010 was developed based on the intelligent Ligase-Dependent Conjugation (iLDC) technology platform of GeneQuantum to enhance the therapeutic window of Trop2 ADC by utilizing a stable linker and a next generation camptothecin analogue. Here we report that GQ1010 demonstrates superior anti-tumor activities against benchmark Trop2 ADCs while maintaining excellent safety profiles, and a potential for a larger therapeutic window, supporting further clinical investigation of GQ1010 in patient with diverse tumors. Method: To characterize GQ1010 in vitro, assays for target binding affinity, internalization, cell cycle, apoptosis, bystander killing, and in vitro cytotoxicity were used. A series of xenograft (CDX) models were used for in vivo efficacy evaluation. Ex vivo plasma stability study was performed to determine the linker stability by monitoring drug-antibody ratio (DAR) change and the payload shedding. In addition, in vivo payload distribution study was performed using a xenograft model. Toxicity study was performed in monkey, and clinical observation, body weight, food consumption, clinical pathology (hematology, coagulation, serum chemistry), and pathology were evaluated. Results: GQ1010 demonstrated more potent in vitro cytotoxicity than DS1062 in diverse Trop2+ cancer cell lines tested. GQ1010 also exhibited superior bystander killing than DS1062. GQ1010 further demonstrated strong in vivo antitumor activities in different CDX models including TNBC, gastric, head and neck (H&N) and pancreatic cancer, and the efficacies were better than DS1062 and Trodelvy®, consistent with the in vitro data. Ex vivo plasma stability data confirmed GQ1010 contains highly stable linker with a minimal DAR reduction and payload shedding, indicating expanded therapeutic window than the benchmark ADCs. Free payload distribution analysis in NCI-N87 model showed high target-specific payload delivery and ~90X payload enrichment in tumor than in plasma, confirming minimal shedding of the payload from GQ1010 during circulation in vivo. In the monkey toxicity study, GQ1010 demonstrated excellent safety without signal of interstitial lung disease (ILD) up to 80 mg/kg dosing. Conclusion: GQ1010 consistently demonstrate superior linker stability, in vitro and in vivo efficacies than DS1062 and Trodelvy®, while maintaining excellent safety. These data suggest GQ1010 has the potential as the next generation Trop2 ADC that can address the critical unmet needs for diverse cancer patients. Citation Format: Yajun Sun, Mingyu Hu, Cao Lv, Yu Si, Xiao Liu, Xinju Gao, Dong Yang, Guangming Chen, Boyu Zhong, Tony Zhang, Lili Shi, Gang Qin, Paul H. Song. Preclinical characterization of GQ1010, a next generation Trop2 ADC with the best-in-class potential against diverse Trop2+ solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1549.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Hello的应助被畅快蓝血采纳,获得10
刚刚
刚刚
连钧发布了新的文献求助10
刚刚
Lucas的应助被刘铭采纳,获得10
刚刚
情怀的应助被光亮的立果采纳,获得10
刚刚
cyy发布了新的文献求助30
1秒前
1秒前
red发布了新的文献求助10
2秒前
3秒前
wanci的应助被咻咻采纳,获得10
3秒前
3秒前
花卷发布了新的文献求助30
3秒前
科研通AI2S的应助被yzw采纳,获得10
5秒前
xin完成签到,获得积分10
6秒前
xiaowu发布了新的文献求助10
6秒前
yu发布了新的文献求助10
6秒前
风趣紫完成签到,获得积分10
6秒前
自由素完成签到,获得积分20
6秒前
繁星jia发布了新的文献求助10
7秒前
LAN完成签到,获得积分10
7秒前
sasakiki发布了新的文献求助10
7秒前
拖鞋不吃鱼完成签到,获得积分10
7秒前
8秒前
orixero的应助被美满的书包采纳,获得10
8秒前
9秒前
天天快乐的应助被lzs采纳,获得10
9秒前
ZZZ完成签到 ,获得积分10
10秒前
细腻飞鸟发布了新的文献求助10
10秒前
10秒前
10秒前
10秒前
10秒前
biu完成签到,获得积分10
11秒前
LAN发布了新的文献求助10
11秒前
天真依玉完成签到,获得积分10
11秒前
12秒前
klicking完成签到,获得积分10
12秒前
天天乐完成签到,获得积分10
12秒前
科研通AI6.4的应助被云汐采纳,获得10
13秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192250
求助须知:如何正确求助?哪些是违规求助? 9578881
关于积分的说明 21862513
捐赠科研通 7791814
什么是DOI,文献DOI怎么找? 3436868
关于科研通互助平台的介绍 2560584
邀请新用户注册赠送积分活动 2483698